Literature DB >> 22548724

Induction of epithelial-mesenchymal transition by transforming growth factor β.

Aristidis Moustakas1, Carl-Henrik Heldin.   

Abstract

Transforming growth factor β (TGFβ) is implicated in human malignancy. Tumors may escape the tumor suppressor activity of TGFβ by mutating some of its signaling components. Carcinoma and stromal cells produce high amounts of TGFβ which promotes epithelial-mesenchymal transition (EMT), tumor cell invasiveness and tumor angiogenesis, while suppressing immune responses against the tumor. Thus, TGFβ has tumor suppressive as well as tumor promoting effects supporting metastasis. TGFβ elicits the EMT response by activating complementary signaling cascades that mobilize embryonic transcription factors that reprogram the epithelial cell so that it acquires both progenitor-like, pro-motility and mesenchymal features. Such nuclear reprogramming of carcinoma cells involves epigenetic and transcriptional regulation, the activity of miRNAs, and modulation of RNA splicing and mRNA translation, leading to the expression of key intracellular and membrane proteins together with a large pool of secreted factors that mediate and account for the phenotypic changes that accompany EMT.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22548724     DOI: 10.1016/j.semcancer.2012.04.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  69 in total

1.  Protein kinase Cα mediates erlotinib resistance in lung cancer cells.

Authors:  Mahlet B Abera; Marcelo G Kazanietz
Journal:  Mol Pharmacol       Date:  2015-02-27       Impact factor: 4.436

Review 2.  Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis.

Authors:  Daisy Y Shu; Frank J Lovicu
Journal:  Prog Retin Eye Res       Date:  2017-08-12       Impact factor: 21.198

3.  Sub-circuits of a gene regulatory network control a developmental epithelial-mesenchymal transition.

Authors:  Lindsay R Saunders; David R McClay
Journal:  Development       Date:  2014-03-05       Impact factor: 6.868

4.  The mitogen-activated protein (MAP) kinases p38 and extracellular signal-regulated kinase (ERK) are involved in hepatocyte-mediated phenotypic switching in prostate cancer cells.

Authors:  Bo Ma; Alan Wells
Journal:  J Biol Chem       Date:  2014-03-11       Impact factor: 5.157

5.  MicroRNA-455-3p mediates GATA3 tumor suppression in mammary epithelial cells by inhibiting TGF-β signaling.

Authors:  Yi Zeng; Tianyang Gao; Wei Huang; Yang Yang; Rongfang Qiu; Yongqiang Hou; Wenqian Yu; Shuai Leng; Dandan Feng; Wei Liu; Xu Teng; Hefen Yu; Yan Wang
Journal:  J Biol Chem       Date:  2019-09-06       Impact factor: 5.157

6.  TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.

Authors:  Neriya Gutgold; Ben Davidson; Liora Jacobs Catane; Arild Holth; Ellen Hellesylt; Claes G Tropé; Anne Dørum; Reuven Reich
Journal:  Virchows Arch       Date:  2017-04-21       Impact factor: 4.064

Review 7.  Reprogramming during epithelial to mesenchymal transition under the control of TGFβ.

Authors:  E-Jean Tan; Anna-Karin Olsson; Aristidis Moustakas
Journal:  Cell Adh Migr       Date:  2014-11-17       Impact factor: 3.405

8.  BMP-7 blocks the effects of TGF-β-induced EMT in cholangiocarcinoma.

Authors:  Kassaporn Duangkumpha; Anchalee Techasen; Watcharin Loilome; Nisana Namwat; Raynoo Thanan; Narong Khuntikeo; Puangrat Yongvanit
Journal:  Tumour Biol       Date:  2014-06-27

Review 9.  The relevance of the TGF-β Paradox to EMT-MET programs.

Authors:  Chevaun D Morrison; Jenny G Parvani; William P Schiemann
Journal:  Cancer Lett       Date:  2013-03-05       Impact factor: 8.679

10.  CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration.

Authors:  Tarek Abbas; Adam C Mueller; Etsuko Shibata; Mignon Keaton; Mario Rossi; Anindya Dutta
Journal:  Mol Cell       Date:  2013-03-07       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.